Member Info for Basser1

Thinking about it a presentation would have required either Tim or John to answer questions on the science. Parker not suited for that role.

I would hazard a guess that a meeting has already been set up via Peel Hunt. No point in presenting if you are there for private discussions. Let’s hope so anyhow.

Parker Tweet 40 minutes ago
‘Looking forward to represent @Sareumplc in San Francisco next week #JKPM23’

Just shows how ridiculously undervalued we are. With SRA737 proven in the clinic and can deal with half of all solid tumour cancers - and SDC1801 can potentially treat up to at least 39 Autoimmune diseases plus covid and pneumonia. If we were still in pennies it would have been at least 6p - not this ridiculous price resulting from consolidation which was just a ploy to give cheap shares to PH Clients.

SCHec - I think you are doing a great job of subtly trying to talk the price down. I have never been totally convinced of your motives.

Sad - thanks for the explanation.

Price gone to 85p. Bastards.Something stinks in the realm of PH

Gunner - Confused by your use of the term “nothing happening for a while” which can be just a very short time or longer depending on context. In Sareum’s situation the term would apply to early January when Sierra Oncology are required to return SRA 737 back to the Cancer Pioneer Fund. Stephen Parker confirmed that several pharmaceuticals had already expressed interest in SRA 737s future development.§
I am not convinced of your motive here - did you get caught on the hop on Friday with the sudden increase in the share price following the very positive news at the AGM?

De Aar - The falling SP due to CTA delay and the return of SRA 737 are not fait accompli. I am happy that you are here and I do not smoke weed .

https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-2074/710713/A-Phase-I-II-Trial-of-Oral-SRA737-a-Chk1-Inhibitor

Published by the AACR (American Association for Cancer Research) on 15 November 2022. Looks like there is a promotion drive to get SRA 737 into trials in America and UK? Apologies if already posted.

The Sareum tweet was 4 days ago - the same day as the Business Weekly article -which was well received. The tweet simply repeats the wording that was in the article so don’t know why some here are tending to make such an issue about it.

SRA737 completes promising Phase1/2 trials and then shelved. Amended licence agreement put in place. No progress after 3 years and SRA 737 returned to Cancer Pioneer Fund. I wonder what Cancer Pioneer Fund and Sareum really think about this.

COL you seem extremely risk averse - might Easy Access Savings Accounts be better for you?

If you are so pessimistic why are you here?

They are desperate for your shares. Hold them tight.

Let’s not overlook that another opportunity beckons for SDC 1801 - as Tim has indicated.

https://genomicc.org/results/covid-drug-baricitinib/

As some have indicated already, Tim was very bullish about the prospects of SDC1801 in Autoimmune. Quote ‘ We believe that SDC1801 has significant potential for superior efficacy in autoimmune disease compared to oral therapies currently AND IN DEVELOPMENT’. So IF this does turn out as planned we should have the Number 1 treatment In the massive autoimmune market - at least 39 potential treatment options for SDC1801 has already been listed by Sareum. That is some statement for Tim to make. OK it is IF but should the results of the phase 1a trial be positive, ie low toxicity and good evidence of efficacy., This will be take off time. Always remember it is IF! But what an exciting share to be in at the moment. Oh and let’s not forget SDC 1802 following on.

RNS statements have to be precise in their terminology. Note ‘’ Subject to Regulatory Approval, we plan to advance our lead candidate SDC1801 into clinical trials shortly’. Dictionary definition of shortly is “ in the immediate future eg we will be arriving shortly’. So news on this should be very near.

Re SRA 737 - might be a blessing in disguise as Sareum and Pioneer fund can now plot its own destiny and avoid the pitfalls in the previous contract. I am expecting a lot of interest in this new opportunity for getting SRA737 into the clinic.

Unknown trades building up - now over £150k’s worth? Was the sudden drop late afternoon yesterday meant to fill these?

There’s another one!